Reducing cisplatin ototoxicity in children: some hope and many questions
Mené sur 125 patients atteints de cancer et âgés de 1 à 18 ans, cet essai de phase III évalue l'efficacité du thiosulfate de sodium pour prévenir la perte auditive induite par une chimiothérapie à base de cisplatine
For decades, cisplatin-related ototoxicity has been dismissed or minimised, especially in paediatric patients. However, not only does hearing impairment create functional limitation in long-term survivors, but increasing evidence shows that it affects other areas, such as speech development, academic achievement, quality of life, and socialisation.1 In the past decade, several attempts to combine otoprotectants with cisplatin, particularly antioxidants, have been made to minimise the effect of cisplatin on hearing.
The Lancet Oncology , commentaire, 2015